Market closed
Regeneron/$REGN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15,106
Website
Regeneron Metrics
BasicAdvanced
$74B
18.15
$38.34
0.08
-
0.51%
Price and volume
Market cap
$74B
Beta
0.08
52-week high
$1,206.81
52-week low
$642.00
Average daily volume
957K
Financial strength
Current ratio
5.567
Quick ratio
4.935
Long term debt to equity
9.908
Total debt to equity
10.012
Interest coverage (TTM)
76.58%
Management effectiveness
Return on assets (TTM)
7.31%
Return on equity (TTM)
15.95%
Valuation
Price to earnings (TTM)
18.154
Price to revenue (TTM)
5.288
Price to book
2.55
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
21.221
Forward dividend yield
0.51%
Growth
Revenue change (TTM)
8.27%
Earnings per share change (TTM)
10.27%
3-year revenue growth (CAGR)
-4.04%
3-year earnings per share growth (CAGR)
-18.94%
What the Analysts think about Regeneron
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Regeneron Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Regeneron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Regeneron News
AllArticlesVideos
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
Accesswire·7 hours ago
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
Accesswire·7 hours ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders
Accesswire·23 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
Mar20
Regeneron
Dividend·Payment
$0.88
Per share
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $74B as of February 22, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 18.15 as of February 22, 2025.
Does Regeneron stock pay dividends?
No, Regeneron (REGN) stock does not pay dividends to its shareholders as of February 22, 2025.
When is the next Regeneron dividend payment date?
Regeneron (REGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.